Bayer Links
Copyright ©
Bayer HealthCare AG
News archive
Bayer’s A1CNow+ as accurate as standard laboratory system
Useful solution for doctor’s offices and emergency labs » more
Contour XT exceeds ISO 15197:2003 accuracy criteria
New innovative technology system provides advanced monitoring accuracy » more
Bayer’s Contour XT demonstrates analytical performance
Exceeds current ISO 15197:2003 requirements compared to conventional chemistry analyzers » more
Bayer receives green light from EU authorities to use Gadovist® 1.0 in children aged two years and older
Bayer HealthCare successfully completed the procedure to get approval for use of the contrast medium Gadovist® 1.0 in children aged two to six years in the Europe Union and markets like Germany, France, Spain, Italy and UK. » more
Bayer HealthCare Expands Research and Manufacturing Capabilities for Interventional Franchise
Bayer HealthCare announced today that it has opened a new, expanded facility for the Interventional franchise within its Medical Care’s Radiology and Interventional business. » more
Positive Phase III Data on Bayer’s Investigational Drug Regorafenib Show Significant Increase in Overall Survival
First presentation of data from CORRECT trial as “Late Breaking Abstract” at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI) » more
Phase III Data of Bayer’s Regorafenib in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Oral Presentation at 2012 ASCO-GI Congress
Late breaking abstract (LBA #385) of Phase III CORRECT study results to be presented on January 21, 2012 » more
Bayer HealthCare to Share Lab Space with Start-Up Companies
Dedicated lab space-model at Bayer HealthCare U.S. Innovation Center to be called CoLaborator™ / Shared lab space will help promising life science companies get their start » more
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Secondary Prevention after an Acute Coronary Syndrome
Submission based on positive results of ATLAS ACS 2-TIMI 51 study / Xarelto is the only new oral anticoagulant to demonstrate significant clinical benefit in this indication when used in combination with standard antiplatelet therapy » more
Bayer: Four potential blockbusters in the Pharma pipeline
Good prospects for Xarelto™, VEGF Trap-Eye, Alpharadin and regorafenib / Market launches in the next 18 months planned / Research and development budget for 2012 approximately EUR 3 billion again » more
Going to great lengths
Professional snowboarder and type 1 diabetic explores his limits at the Iron Man » more
Bayer’s Xarelto® Approved in the EU for the Prevention of Stroke in Patients with AF and in the Treatment of DVT
In stroke prevention in AF, Xarelto is the only oral anticoagulant offering patients a once-daily, highly effective therapy without need for routine coagulation monitoring / For the treatment of DVT and the prevention of recurrent DVT and PE, Xarelto is the first oral anticoagulant to offer patients both efficacy and the convenience of a single-drug solution, without the need for injections or monitoring / Xarelto is now approved in the EU across three indications in the area of venous and arterial thromboembolism (VAT) » more
New Intrauterine System for long-term contraception submitted for marketing authorization both in the EU and the U.S.
Once approved, the new low dose IUS will offer young women contraception for up to three years » more
Integrated diabetes software for behavioral changes and improved glycemic control
Transforming blood glucose data into meaningful insights » more
Young leaders to raise awareness of diabetes
Bayer HealthCare supports the IDF Young Leaders in Diabetes Programme » more
Education can significantly improve glycaemic control
British team awarded for providing a structured pathway to reduce HbA1c levels » more
2010 European Journalists' Prize goes to Dr. Britta Julia Dombrowe and John A. Kantara
The Association of German Medical Journalists [Verband Deutscher Medizinjournalisten, VDMJ] presents the European Journalists’ Prize, which is sponsored by Bayer HealthCare AG and endowed with EUR 7,500, for the ninth time. » more
U.S. FDA Approves EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Approval based on positive results of VIEW 1 and VIEW 2 clinical trials / Regeneron Pharmaceuticals will market EYLEA™ in the U.S. » more
Innovations from the world of research at Bayer
Personalized medicine against cancer / Creating new active crop protection ingredients with biotechnology / Electric mobility: materials for the cars of the future » more
Bayer plans further expansion in Asia
Sales in the region to grow to well over EUR 11 billion by 2015 / Some EUR 6 billion in sales expected in Greater China alone / Plans to expand production, distribution network and research / Further capital expenditures of EUR 1.8 billion in Asia by 2015 / New TDI production facility dedicated in Shanghai » more
Bayer’s Xarelto® (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study
Rivaroxaban Meets Primary Efficacy Endpoint, Significantly Reducing the Composite of Cardiovascular Death, Myocardial Infarction and Stroke / Rivaroxaban 2.5 mg twice daily Significantly Reduced Both the Rate of Cardiovascular Death and the Incidence of All-Cause Mortality by more than 30% / Major Bleeding in Patients Receiving Rivaroxaban was Significantly Increased but there was no Increase in the Risk of Fatal Bleeding / Study Results Presented as a Late-Breaker at the Scientific Sessions of the American Heart Association and Published by the New England Journal of Medicine » more
Bayer cooperates with Ludwig Boltzmann Institute for Translational Heart Failure Research
Newly founded institute studies the causes of heart failure and seeks new therapeutic options » more
US FDA Approves Bayer’s Xarelto® (Rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation
Rivaroxaban is highly effective and well tolerated in protecting patients with Atrial Fibrillation from stroke / Rivaroxaban is the only anticoagulant with once-daily fixed dosing for stroke prevention in patients with atrial fibrillation / Rivaroxaban does not require routine coagulation monitoring, making it more convenient to both patients and physicians » more
Bayer and AgraQuest Expand Distribution Agreement for Asia/Pacific and South America regarding Poultry Nutrition Supplement
Agreement will Allow Bayer to Distribute Patented AgraQuest Technology into Poultry Markets » more
After a good third quarter: Bayer confirms Group outlook
Sales up by 4.8 percent (adjusted) to EUR 8,670 million / Continuing growth momentum in the emerging markets (adjusted: plus 9.5 percent) / Operating result (EBIT) increased by 94.9 percent to EUR 1,099 million / EBITDA before special items up by 8.5 percent to EUR 1,805 million / HealthCare and CropScience margins distinctly improved – MaterialScience weaker / Net income more than doubled to EUR 642 million (plus 125.3 percent) » more
Phase III Trial of Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
Trial stopped based on positive data from a pre-planned interim analysis » more
Search
Page tools
click to adjust font size
Social Bookmarks
Bayer HealthCare Links
Newsroom
